Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.58 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17978136 | 0.88 | MAPK14 (0.59) | MAPK14PTPRC | |
| SCHEMBL24927780 | 0.86 | MAPK14 (0.59) | MAPK14SRD5A1SRD5A2 | |
| SCHEMBL20644283 | 0.85 | MAPK14 (0.59) | MAPK14 | |
| SCHEMBL13548832 | 0.84 | MAPK14 (0.56) | MAPK14SRD5A1SRD5A2PTPRC | |
| SCHEMBL26124045 | 0.84 | MAPK14 (0.63) | MAPK14 | |
| SCHEMBL9372469 | 0.83 | MAPK14 (0.57) | MAPK14SRD5A1SRD5A2 | |
| SCHEMBL11684948 | 0.83 | SRD5A1 (0.72) | MAPK14SRD5A1SRD5A2PTPRC | |
| SCHEMBL13548810 | 0.82 | MAPK14 (0.71) | MAPK14 | |
| SCHEMBL8142034 | 0.81 | SRD5A1 (0.56) | MAPK14SRD5A1SRD5A2PTPRC | |
| SCHEMBL24926960 | 0.80 | MAPK14 (0.59) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023186881-A1 | P38 MAP KINASE INHIBITORS FOR USE IN THE TREATMENT OF COLORECTAL CANCER | BADEN-WÜRTTEMBERG STIFTUNG GGMBH (DE) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023186881-A1 | P38 MAP KINASE INHIBITORS FOR USE IN THE TREATMENT OF COLORECTAL CANCER | BADEN-WÜRTTEMBERG STIFTUNG GGMBH (DE) | 2023-10-05 | — | — | WO | disclosed |
| US-20230017312-A1 | CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS | SYNOVO GMBH (DE) | 2023-01-19 | — | — | US | disclosed |
| WO-2021038292-A1 | CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS | SYNOVO GMBH (DE) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017312-A1 | CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS | MAPK1, MAPK8, MAPK7 | MAPK14 10/4885SRD5A1 3197/4885SRD5A2 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.